Literature DB >> 14989709

The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD.

A Bishara1, D De Santis, C C Witt, C Brautbar, F T Christiansen, R Or, A Nagler, S Slavin.   

Abstract

HLA allele mismatches will provoke T-cell alloreactivity after allogeneic stem cell transplantation. As donors and recipients are usually HLA matched, the public HLA epitopes that are recognized by natural killer (NK) cells (NK epitopes) are rarely mismatched, and therefore there is rarely potential for NK alloreactivity arising from the absence of ligands for inhibitory killer immunoglobulin-like receptors (KIR). Transplants using related donors sharing only one haplotype (haploidentical donors) represent a setting in which NK epitopes are often mismatched, thus resulting in the potential for NK alloreactivity. We have analyzed engraftment, acute graft vs host disease (GVHD), leukemia relapse, and survival in 62 haploidentical transplants in relationship with potential NK alloreactivity, inhibitory, and activating KIR genes of class I HLA NK epitopes. Potential NK alloreactivity in the rejection direction was not associated with any outcome variable. Potential NK alloreactivity in the GVHD direction was associated with an increased incidence of severe GVHD and poorer patient survival but not with non-engraftment nor leukemia relapse. A higher number of activating KIR receptors in the genome of the donor was associated with a higher prevalence of GVHD. These results suggest that lack of extensive T-cell depletion in haploidentical transplantation is associated with high GVHD rates and diminishes the benefits of NK-cell alloreactivity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14989709     DOI: 10.1111/j.0001-2815.2004.00182.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  45 in total

1.  Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors.

Authors:  D-F Chen; V K Prasad; G Broadwater; N L Reinsmoen; A DeOliveira; A Clark; K M Sullivan; J P Chute; M E Horwitz; C Gasparetto; G D Long; Y Yang; N J Chao; D A Rizzieri
Journal:  Bone Marrow Transplant       Date:  2011-12-05       Impact factor: 5.483

2.  The unexpected effect of cyclosporin A on CD56+CD16- and CD56+CD16+ natural killer cell subpopulations.

Authors:  Hongbo Wang; Bartosz Grzywacz; David Sukovich; Valarie McCullar; Qing Cao; Alisa B Lee; Bruce R Blazar; David N Cornfield; Jeffrey S Miller; Michael R Verneris
Journal:  Blood       Date:  2007-05-10       Impact factor: 22.113

Review 3.  Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors.

Authors:  H J Symons; E J Fuchs
Journal:  Bone Marrow Transplant       Date:  2008-08-04       Impact factor: 5.483

Review 4.  Strategies to enhance NK cell function for the treatment of tumors and infections.

Authors:  Jacquelyn Freund-Brown; Leilani Chirino; Taku Kambayashi
Journal:  Crit Rev Immunol       Date:  2018       Impact factor: 2.214

Review 5.  Can we make a better match or mismatch with KIR genotyping?

Authors:  Rohtesh S Mehta; Katayoun Rezvani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2016-12-02

Review 6.  The Past, Present, and Future of NK Cells in Hematopoietic Cell Transplantation and Adoptive Transfer.

Authors:  Frank Cichocki; Michael R Verneris; Sarah Cooley; Veronika Bachanova; Claudio G Brunstein; Bruce R Blazar; John Wagner; Heinrich Schlums; Yenan T Bryceson; Daniel J Weisdorf; Jeffrey S Miller
Journal:  Curr Top Microbiol Immunol       Date:  2016       Impact factor: 4.291

Review 7.  Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies.

Authors:  Mary Eapen; Paul O'Donnell; Claudio G Brunstein; Juan Wu; Kate Barowski; Adam Mendizabal; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2014-05-23       Impact factor: 5.742

8.  Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation.

Authors:  Heather J Symons; M Sue Leffell; Nancy D Rossiter; Marianna Zahurak; Richard J Jones; Ephraim J Fuchs
Journal:  Biol Blood Marrow Transplant       Date:  2009-12-02       Impact factor: 5.742

9.  The diversity of KIR gene in Chinese Northern Han population and the impact of donor KIR and patient HLA genotypes on outcome following HLA-identical sibling allogeneic hematopoietic stem cell transplantation for hematological malignancy in Chinese people.

Authors:  Li Ping Dou; De Hua Zheng; Chang Wang; Jun Hua Liu; Jing Fen Sun; Hai Jie Jin; Chun Ji Gao; Li Yu; Wan Ming Da
Journal:  Int J Hematol       Date:  2008-05       Impact factor: 2.490

10.  Impact of natural killer cell dose and donor killer-cell immunoglobulin-like receptor (KIR) genotype on outcome following human leucocyte antigen-identical haematopoietic stem cell transplantation.

Authors:  J Clausen; D Wolf; A L Petzer; E Gunsilius; P Schumacher; B Kircher; G Gastl; D Nachbaur
Journal:  Clin Exp Immunol       Date:  2007-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.